Oncology NEWS International April 2009 Vol. 18 No. 4

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Daniel C. McFarland, DO;Michelle Riba, MD

December 22nd 2025

Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Kristi Rosa

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath

December 15th 2025

Zanubrutinib Therapies Yield Durable Results in High-Risk, Treatment-Naïve CLL/SLL

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

ONCOLOGY Staff

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Andrea Eleazar, MHS

Novel Agent Shows Early Activity in Phase 2 Recurrent Thymoma Study

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Related Content

Russ Conroy

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Daniel C. McFarland, DO;Michelle Riba, MD

December 22nd 2025

Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Kristi Rosa

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath

December 15th 2025

Zanubrutinib Therapies Yield Durable Results in High-Risk, Treatment-Naïve CLL/SLL

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ONCOLOGY Staff

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Andrea Eleazar, MHS